Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...

Opportunities in the NSCLC market include the adoption of targeted and immunotherapies such as PD-1/PD-L1 inhibitors, the potential in Asia Pacific driven by rising prevalence, and advancements in ...

Alpine Bio has developed an “insanely soluble” soy protein isolate with “whey-like characteristics" from non-GMO soy flour.

Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio ...

Johnson & Johnson ( NYSE: JNJ) Q3 2025 Earnings Call October 14, 2025 8:30 AM EDT Good morning, and welcome to Johnson & Johnson's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] ...

The Global Hyperhidrosis Treatment Market Size is projected to grow at a CAGR of 5.89% from 2026 to 2032, according to a new report ...

(Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI ® (enzalutamide), in combination with leuprolide ...

The compelling clinical activity, durable response and acceptable tolerability profile seen with elironrasib underscore the potential of this differentiated RAS (ON) G12C-selective inhibitor, ...

Epidermal growth factor receptor non-small cell lung cancer (EGFR NSCLC) is a lung cancer subtype driven by EGFR gene mutations, leading to rapid tumor growth. It's prevalent particularly in Asian ...